ebglyss

Generic: lebrikizumab-lbkz

Labeler: eli lilly and company
NDC Directory HUMAN PRESCRIPTION DRUG BLA Inactive Finished

Drug Facts

Product Profile

Brand Name ebglyss
Generic Name lebrikizumab-lbkz
Labeler eli lilly and company
Dosage Form INJECTION, SOLUTION
Routes
SUBCUTANEOUS
Active Ingredients

lebrikizumab 250 mg/2mL

Manufacturer
Eli Lilly and Company

Identifiers & Regulatory

Product NDC 0002-7797
Product ID 0002-7797_44cd7f6e-d6f3-4073-9c40-46b3bb4b6091
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category BLA
Application Number BLA761306
Listing Expiration 2026-12-31
Marketing Start 2024-09-13

Pharmacologic Class

Established (EPC)
interleukin-13 antagonist [epc]
Mechanism of Action
interleukin-13 antagonists [moa]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 00027797
Hyphenated Format 0002-7797

Supplemental Identifiers

RxCUI
2693784 2693791 2693903 2693907
UNII
U9JLP7V031
NUI
N0000193985 N0000193986

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name ebglyss (source: ndc)
Generic Name lebrikizumab-lbkz (source: ndc)
Application Number BLA761306 (source: ndc)
Routes
SUBCUTANEOUS
source: ndc

Resolved Composition

Strengths
  • 250 mg/2mL
source: ndc
Packaging
  • 1 SYRINGE in 1 CARTON (0002-7797-11) / 2 mL in 1 SYRINGE (0002-7797-01)
  • 1 SYRINGE in 1 CARTON (0002-7797-61) / 2 mL in 1 SYRINGE
source: ndc

Packages (2)

0002-7797-11 1 SYRINGE in 1 CARTON (0002-7797-11) / 2 mL in 1 SYRINGE (0002-7797-01) 0002-7797-61 1 SYRINGE in 1 CARTON (0002-7797-61) / 2 mL in 1 SYRINGE

Ingredients (1)

lebrikizumab (250 mg/2mL)

Linked Drug Pages (1)

EBGLYSS ndc-match (0.9)

Raw FDA Data

View complete raw FDA NDC JSON payload 
{"route": ["SUBCUTANEOUS"], "spl_id": "44cd7f6e-d6f3-4073-9c40-46b3bb4b6091", "openfda": {"nui": ["N0000193985", "N0000193986"], "unii": ["U9JLP7V031"], "rxcui": ["2693784", "2693791", "2693903", "2693907"], "spl_set_id": ["7a774ea2-acde-4aaa-9a8f-ccba5a5b1d5f"], "pharm_class_epc": ["Interleukin-13 Antagonist [EPC]"], "pharm_class_moa": ["Interleukin-13 Antagonists [MoA]"], "manufacturer_name": ["Eli Lilly and Company"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 SYRINGE in 1 CARTON (0002-7797-11)  / 2 mL in 1 SYRINGE (0002-7797-01)", "package_ndc": "0002-7797-11", "marketing_start_date": "20240913"}, {"sample": true, "description": "1 SYRINGE in 1 CARTON (0002-7797-61)  / 2 mL in 1 SYRINGE", "package_ndc": "0002-7797-61", "marketing_start_date": "20240913"}], "brand_name": "EBGLYSS", "product_id": "0002-7797_44cd7f6e-d6f3-4073-9c40-46b3bb4b6091", "dosage_form": "INJECTION, SOLUTION", "pharm_class": ["Interleukin-13 Antagonist [EPC]", "Interleukin-13 Antagonists [MoA]"], "product_ndc": "0002-7797", "generic_name": "lebrikizumab-lbkz", "labeler_name": "Eli Lilly and Company", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "EBGLYSS", "active_ingredients": [{"name": "LEBRIKIZUMAB", "strength": "250 mg/2mL"}], "application_number": "BLA761306", "marketing_category": "BLA", "marketing_start_date": "20240913", "listing_expiration_date": "20261231"}